Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

6,270JPY
17 Jul 2019
Change (% chg)

¥190 (+3.12%)
Prev Close
¥6,080
Open
¥6,099
Day's High
¥6,285
Day's Low
¥6,064
Volume
2,289,400
Avg. Vol
2,055,157
52-wk High
¥6,285
52-wk Low
¥3,277

Select another date:

Fri, Jun 21 2019

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

UPDATE 1-FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business

TOKYO Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

UPDATE 2-Daiichi Sankyo looking to sell OTC drug unit for about $900 mln -Nikkei Business

* Company denies it is negotiating sale of unit (Adds company comment, background)

Daiichi Sankyo looking to sell OTC drug unit for about $900 mln - Nikkei Business

TOKYO, May 23 Japan's Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

UPDATE 1-FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

May 14 Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

FDA advisory panel votes against Daiichi Sankyo's cancer treatment

May 14 Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

Select another date: